SCHEMBL413347

SCHEMBL413347

Fc1ccc2scc(Br)c2c1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.45
CA2 P00918 1/20 0.45
TP53 P04637 5/20 0.43
CYP2A6 P11509 3/20 0.43
LMNA P02545 1/20 0.43
MTNR1A P48039 1/20 0.43
MTNR1B P49286 1/20 0.43
THRB P10828 1/20 0.41
MPI P34949 4/20 0.37
PMM2 O15305 2/20 0.37
APOBEC3G Q9HC16 2/20 0.37
G6PD P11413 1/20 0.37
PHOSPHO1 Q8TCT1 1/20 0.35
TLR9 Q9NR96 1/20 0.35
MIF P14174 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713455 0.83 MAPT (0.46) MAPTCA2TP53LMNAMTNR1A
SCHEMBL2114297 0.80 CA2 (0.55) MAPTCA2TP53CYP2A6LMNA
SCHEMBL3164828 0.77 CYP2A6 (0.66) MAPTCA2TP53CYP2A6TLR9
SCHEMBL4730693 0.77 CA2 (0.47) MAPTCA2TP53CYP2A6LMNA
SCHEMBL84297 0.77 MAPT (0.44) MAPTCA2TP53CYP2A6LMNA
SCHEMBL4877866 0.77 CYP2A6 (0.60) MAPTCA2TP53CYP2A6LMNA
SCHEMBL545092 0.77 CYP2A6 (0.60) MAPTCA2TP53CYP2A6LMNA
SCHEMBL2095397 0.77 MAPT (0.44) MAPTCA2TP53CYP2A6LMNA
SCHEMBL5397554 0.76 CYP2A6 (0.64) MAPTCA2TP53CYP2A6LMNA
SCHEMBL7541080 0.74 MAPT (0.45) MAPTCA2TP53CYP2A6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026103853-A1 TSHR ANTAGONIST COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARING SAME, AND USE THEREOF 长春金赛药业有限责任公司 2026-05-21 WO disclosed
US-20220298135-A1 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2022-09-22 US disclosed
EP-4010328-A1 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS Domain Therapeutics (FR) 2022-06-15 EP disclosed
CN-114269730-A 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists 多曼治疗学公司 2022-04-01 CN disclosed
WO-2021023813-A1 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2021-02-11 WO disclosed
US-20190071457-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DOW AGROSCIENCES LLC 2019-03-07 US disclosed
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. 2017-10-05 US disclosed
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS Janssen Biopharma, Inc. 2017-10-05 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
US-9724351-B2 Compounds for the treatment of paramoxyvirus viral infections ALIOS BIOPHARMA, INC. (US) 2017-08-08 US disclosed
EP-2102157-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2009-09-23 EP disclosed
WO-2008074703-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 WO disclosed
WO-2008074703-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 WO disclosed
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2008-06-19 US disclosed
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2008-06-19 US disclosed
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2008-06-19 US disclosed
EP-0526588-B1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK AS (DK) 1994-03-09 EP disclosed
EP-0526588-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE. NOVO NORDISK AS (DK) 1993-02-10 EP disclosed
US-5182279-A Antiepileptic, anticonvulsant, anxiolytic, antiischemic NOVO NORDISK A/S (DK) 1993-01-26 US disclosed
WO-1991016325-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1991-10-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170283429-A1 COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS MAVS, SARS1, ZC3HAV1 MAPT 4377/4885CA2 3446/4885TP53 3470/4885
US-20190071457-A1 4-AMINO-6-(HETEROCYCLIC)PICOLINATES AND 6-AMINO-2-(HETEROCYCLIC)PYRIMIDINE-4-CARBOXYLATES AND THEIR USE AS HERBICIDES DDT, DDC, P2RX6 MAPT 2547/4885CA2 824/4885TP53 934/4885
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof CNKSR1, RB1, AR MAPT 3385/4885CA2 4403/4885TP53 829/4885
US-20220298135-A1 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS NPFFR2, NPFFR1, OPRL1 MAPT 3231/4885CA2 4413/4885TP53 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.